Dual-drug nanoplatform HPA@NPs reprograms the fibrotic microenvironment by suppressing EMT and M2 macrophage polarization in pulmonary fibrosis
International Immunopharmacology · 2026
DOI: 10.1016/j.intimp.2026.116362 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026. Verfasst von An Chang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Administration, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121000, China; Key Surgical Laboratory of Edu…. Hauptthemen laut MEDLINE: Pulmonary Fibrosis, Hyaluronic Acid, Macrophages, Nanoparticles. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Liaoning Provincial Natural Science Foundation.
Abstract (Originalsprache)
Pulmonary fibrosis (PF) is a progressive and lethal interstitial lung disease, characterized by excessive extracellular matrix deposition and architectural distortion of the lung parenchyma. Its pathogenesis involves interconnected pathological events, including dysregulated epithelial-mesenchymal transition (EMT), chronic inflammation driven by M2-polarized macrophages, and abnormal fibroblast activation. These intertwined mechanisms contribute to the limited efficacy of current anti-fibrotic therapies, which often fail to achieve lesion-specific targeting and disease reversal. Moreover, the clinical utility of existing drugs is further hampered by poor bioavailability and insufficient accumulation at fibrotic sites. To overcome these challenges, we developed a multifunctional nanotherapeutic platform, termed HPA@NPs, through co-assembly of hyaluronic acid-platycodin D (HA-PD) and aspirin-platycodin D (ASA-PD) conjugates. This nanosystem enables concurrent modulation of multiple PF-relevant pathological features. Physicochemical characterization showed that HPA@NPs possess uniform nanoscale size, low critical aggregation concentration, and excellent colloidal stability, supporting prolonged blood circulation. In vitro, HPA@NPs showed efficient cellular uptake consistent with their HA-based design and were accompanied by inhibition of EMT, fibroblast activation, and M2 macrophage polarization, together with reduced expression of IL-10 and Arg-1. In bleomycin-induced PF mice, HPA@NPs significantly improved pulmonary function and attenuated histopathological damage. At the molecular level, HPA@NPs down-regulated fibrosis-related markers (Col1a1, TGF-β1, α-SMA), while up-regulating the epithelial tight-junction protein ZO-1 and down-regulating mesenchymal markers (N-cadherin, vimentin), confirming effective reversal of EMT. The therapeutic outcome of HPA@NPs surpassed that of monotherapy, highlighting a synergistic anti-fibrotic effect. Importantly, HPA@NPs exhibited no detectable cytotoxicity, hemolytic activity, or major organ toxicity at therapeutic doses, demonstrating favorable biocompatibility. In summary, HPA@NPs integrate precise targeting, multi-pathway synergy, and excellent biosafety, offering a promising translational strategy for PF treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Drug Administration, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121000, China; Key Surgical Laboratory of Educational Administration of Liaoning Province, Jinzhou Medical Universi…
- Key Surgical Laboratory of Educational Administration of Liaoning Province, Jinzhou Medical University, Jinzhou 121000, China. Electronic address: wangy5@jzmu.edu.cn.
- Department of Drug Administration, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121000, China.
- School of Pharmacy, Jinzhou Medical University, Jinzhou 121000, China.
- Pain Management Department, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121000, China. Electronic address: menglq@jzmu.edu.cn.
- Department of Drug Administration, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121000, China. Electronic address: shij@jzmu.edu.cn.
Förderung
- Liaoning Provincial Natural Science Foundation
Zitieren
APA
Chang, A., Wang, Y., Cui, Z., Liu, Y. Y., Meng, L. Q., Jia-Shi, Qin, Z. Y., & Gong, J. N. (2026). Dual-drug nanoplatform HPA@NPs reprograms the fibrotic microenvironment by suppressing EMT and M2 macrophage polarization in pulmonary fibrosis. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2026.116362
Vancouver
Chang A, Wang Y, Cui Z, Liu YY, Meng LQ, Jia-Shi, et al. Dual-drug nanoplatform HPA@NPs reprograms the fibrotic microenvironment by suppressing EMT and M2 macrophage polarization in pulmonary fibrosis. International Immunopharmacology. 2026. doi:10.1016/j.intimp.2026.116362
BibTeX
@article{Chang2026,
author = {Chang, An and Wang, Yi and Cui, Zan and Liu, Yuan-Yuan and Meng, Ling-Qi and Jia-Shi and Qin, Zhi-Yong and Gong, Jia-Ning},
title = {Dual-drug nanoplatform HPA@NPs reprograms the fibrotic microenvironment by suppressing EMT and M2 macrophage polarization in pulmonary fibrosis},
journal = {International Immunopharmacology},
year = {2026},
doi = {10.1016/j.intimp.2026.116362}
}
EUVIMED